Effect of ethnicity on the progression of diabetic kidney disease independent of glycemic control

American Journal of Nephrology

Volumn 30, Issue 3, 2009, Pages 261-267

  Salifu, Moro O ^a   Shah, Syed ^a   Iqbal, Muhammad H ^a   Nabi, Mushtaq ^a   Hayat, Amir ^a   Whaley Connell, Adam T ^b   Sowers, James R ^b   McFarlane, Samy I ^a  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b University of Missouri   (United States)

Author keywords

Diabetic kidney disease, ethnicity; Glycemic control

Indexed keywords

HEMOGLOBIN A1C;

AFRICAN AMERICAN; AGED; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AFRICAN AMERICANS; AGED; BLOOD GLUCOSE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 66149108399     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000223527     Document Type: Article

References (38)

1. US Renal Data System. USRDS 2004 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2004.
2. National Center for Chronic Disease Prevention and Health Promotion: National Diabetes Fact Sheet. 2002. Available at: http://www.cdc.gov/diabetes/ pubs/factsheet.htm. Accessed February 20, 2004.
3. Hebert LA, Kusek JW, Greene T, et al: Effects of blood pressure control on progressive renal disease in Blacks and Whites. Modification of Diet in Renal Disease Study Group. Hypertension 1997; 30: 428-435.
4. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
5. Gaede P, Vedel P, Parving HH, et al: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
6. The Epidemiology of Diabetes Interventions and Complications (EDIC) study: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy. JAMA 2003; 290: 2159-2167.
7. Adler AI, Stevens RJ, Manley SE, et al: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.
8. Young BA, Maynard C, Boyko EJ: Racial differences in diabetic nephropathy, cardiovascular disease, and mortality in a national population of veterans. Diabetes Care 2003; 26: 2392-2399.
9. Wendel CS, Shah JH, Duckworth WC, et al: Racial and ethnic disparities in the control of cardiovascular disease risk factors in Southwest American veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study. BMC Health Serv Res 2006; 6: 58.
10. Levey AS, Bosch JP, Lewis JB, et al: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
11. Obermayr RP, Temml C, Knechtelsdorfer M, et al: Predictors of new-onset decline in kidney function in a general middle European population. Nephrol Dial Transplant 2008; 23: 1265-1273.
12. Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13-18.
13. Klag MJ, Whelton PK, Randall BL, et al: Endstage renal disease in African-American and White men. 16-year MRFIT findings. JAMA 1997; 277: 1293-1298.
14. Perry HM Jr, Miller JP, Fornoff JR, et al: Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 1995; 25: 587-594.
15. Shulman NB, Ford CE, Hall WD, et al: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-Up Program Cooperative Group. Hypertension 1989; 13(suppl): I80-I93.
16. Toto RD, Mitchell HC, Smith RD, et al: 'Strict' blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int 1995; 48: 851-859.
17. Brazy PC, Stead WW, Fitzwilliam JF: Progression of renal insufficiency: role of blood pressure. Kidney Int 1989; 35: 670-674.
18. Agodoa LY, Appel L, Bakris GL, et al: Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285: 2719-2728.
19. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ: Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997; 278: 2069-2074.
20. Appel GB, Radhakrishnan J, Avram MM, et al: Analysis of metabolic parameters as predictors of risk in the RENAAL study. Diabetes Care 2003; 26: 1402-1407.
21. Hsu CY, Bates DW, Kuperman GJ, et al: Diabetes, hemoglobin A1c, cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population. Am J Kidney Dis 2000; 36: 272-281.
22. McClellan WM, Langston RD, Presley R: Medicare patients with cardiovascular disease have a high prevalence of chronic kidney disease and a high rate of progression to end-stage renal disease. J Am Soc Nephrol 2004; 15: 1912-1919.
23. Centers for Disease Control and Prevention: Prevalence of chronic kidney disease and associated risk factors - United States, 1999-2004. MMWR Morb Mortal Wkly Rep 2007; 56: 161-165.
24. Levey AS, Coresh J, Balk E, et al: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147.
25. Lewis EJ, Hunsicker LG, Bain RP, et al: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329: 1456-1462.
26. Ruggenenti P, Perna A, Gherardi G, et al: Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 1998; 352: 1252-1256.
27. Parving HH, Lehnert H, Brochner-Mortensen J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878. (Pubitemid 34940826)
28. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869. (Pubitemid 34940825)
29. Mogensen CE, Neldam S, Tikkanen I, et al: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin-dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-1444.
30. Nakao N, Yoshimura A, Morita H, et al: Combination treatment of angiotensin-II receptor blocker and angiotensin-convertingenzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117-124. (Pubitemid 36092015)
31. Ward MM: Medical insurance, socioeconomic status, and age of onset of end-stage renal disease in patients with lupus nephritis. J Rheumatol 2007; 34: 2024-2027.
32. Mix TC, St Peter WL, Ebben J, et al: Hospitalization during advancing chronic kidney disease. Am J Kidney Dis 2003; 42: 972-981.
33. Moreira LB, Fernandes PF, Mota RS, et al: Medication noncompliance in chronic kidney disease. J Nephrol 2008; 21: 354-362.
34. Mandayam S, Mitch WE: Dietary protein restriction benefits patients with chronic kidney disease. Nephrology (Carlton) 2006; 11: 53-57.
35. Karter AJ, Ferrara A, Liu JY, et al: Ethnic disparities in diabetic complications in an insured population. JAMA 2002; 287: 2519-2527.
36. Young BA, Katon WJ, Von Korff M, et al: Racial and ethnic differences in microalbuminuria prevalence in a diabetes population: the pathways study. J Am Soc Nephrol 2005; 16: 219-228.
37. Oldroyd J, Banerjee M, Heald A, et al: Diabetes and ethnic minorities. Postgrad Med J 2005; 81: 486-490.
38. Ruggenenti P, Perna A, Gherardi G, et al: Renoprotective properties of ACE inhibition in non-diabetic nephropathies with nonnephrotic proteinuria. Lancet 1999; 354: 359-364.